Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Carmine N. Stengone | CEO and President, Director | May 24, 2024 | |||
Daniel S. Lorrain | Chief Scientific Officer | May 24, 2024 | |||
Peter Slover | Chief Financial Officer | May 24, 2024 | |||
Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | Aug 13, 2024 | |||
Todd R. Brady | Director | May 24, 2024 | |||
Lori Lyons-Williams | Director | May 24, 2024 | |||
Evert Schimmelpennink | Director | May 24, 2024 | |||
Olivia C. Ware | Director | May 24, 2024 | |||
Versant Venture Capital VI, L.P. | 10%+ Owner | Apr 9, 2024 | |||
Troy A. Ignelzi | Director | May 24, 2024 | |||
Johnson & Johnson | 10%+ Owner | Apr 9, 2024 | |||
John Stephen Healy | General Counsel and Corp Sec | Jun 3, 2024 | |||
Sarah Boyce | Director | Jun 24, 2024 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|